Clara cell protein in nasal lavage fluid and nasal nitric oxide - biomarkers with anti-inflammatory properties in allergic rhinitis

Clinical and Molecular Allergy

Volumn 10, Issue , 2012, Pages

  Irander, Kristina ^a   Palm, Jörgen P ^b   Borres, Magnus P ^c,d   Ghafouri, Bijar ^e  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d Thermo Fisher Scientific   (United States)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Allergic rhinitis; Anti inflammatory effects; Basophils; CC16; Eosinophils; Mast cells; Metachromatic cells; Nasal lavage fluid; Nasal nitric oxide; Upper airways

Indexed keywords

CLARA CELL PROTEIN; NITRIC OXIDE;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASOPHIL; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHIL; HAY FEVER; HUMAN; MAST CELL; MICROSCOPY; NOSE MUCUS; PERENNIAL RHINITIS; HUMAN CELL; WESTERN BLOTTING;

EID: 84856574693     PISSN: None     EISSN: 14767961     Source Type: Journal    
DOI: 10.1186/1476-7961-10-4     Document Type: Article

References (30)

1. Bernard A, Lauwerys R. Low-molecular-weight proteins as markers of organ toxicity with special reference to Clara cell protein. Toxicol Lett 1995, 77:145-151. 10.1016/0378-4274(95)03284-3, 7618128.
2. Broeckaert F, Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Allergy 2000, 30:469-475. 10.1046/j.1365-2222.2000.00760.x, 10718843.
3. Lakind JS, Holgate ST, Ownby DR, Mansur AH, Helms PJ, Pyatt D, Hays SM. A critical review of the use of Clara cell secretory protein (CC16) as a biomaker of acute or chronic pulmonary effects. Biomarkers 2007, 12:445-467. 10.1080/13547500701359327, 17701745.
4. Lindahl M, Svartz J, Tagesson C. Demonstration of different forms of the anti-inflammatory proteins lipocortin-1 and Clara cell protein-16 in human nasal and bronchoalveolar lavage fluids. Electrophoresis 1999, 20:881-890. 10.1002/(SICI)1522-2683(19990101)20:4/5<881::AID-ELPS881>3.0.CO;2-6, 10344263.
5. Lindahl M, Irander K, Tagesson C, Ståhlbom B. Nasal lavage fluid and proteomics as means to identify the effects of the irritating epoxy chemical dimethylbenzylamine. Biomarkers 2004, 9:56-70. 10.1080/13547500410001662005, 15204311.
6. Gomes EC, Stone V, Florida-James G. Impact of heat and pollution on oxidative stress and CC16 secretion after 8 km run. Eur J Appl Physiol 2011, 111:2089-2097. 10.1007/s00421-011-1839-x, 21267745.
7. Johansson S, Keen C, Ståhl A, Wennergren G, Benson M. Low levels of CC16 in nasal fluid of children with birch pollen-induced rhinitis. Allergy 2005, 60:638-642. 10.1111/j.1398-9995.2005.00775.x, 15813809.
8. Benson M, Jansson L, Adner M, Luts A, Uddman R, Cardell LO. Gene profiling reveals decreased expression of uteroglobin and other anti-inflammatory genes in nasal fluid cells from patients with intermittent allergic rhinitis. Clin Exp Allergy 2005, 35:473-478. 10.1111/j.1365-2222.2005.02206.x, 15836756.
9. Benson M, Fransson M, Martinsson T, Naluai T, Uddman R, Cardell LO. Inverse relation between nasal fluid Clara Cell Protein 16 levels and symptoms and signs of rhinitis in allergen-challenged patients with intermittent allergic rhinitis. Allergy 2007, 62:178-183.
10. Lundberg JO. Nitric oxide and the paranasal sinuses. Anat Rec 2008, 291:1479-1484.
11. Borres MP, Irander K, Björkstén B. Nasal metachromatic cells in infants in relation to allergic disease and family history of atopy. Pediatr Allergy Immunol 1991, 4:184-189.
12. Borres MP, Irander K, Björkstén B. Nasal metachromatic cells in infancy in relation to the appearance of atopic disease during the first 6 years of life. Allergy 1997, 52:770-774. 10.1111/j.1398-9995.1997.tb01237.x, 9265995.
13. Irander K, Borres MP. An 18-year follow-up of allergy development related to nasal metachromatic cell findings during infancy. Allergol Int 2010, 59:193-200. 10.2332/allergolint.09-OA-0132, 20299825.
14. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
15. American Thoracic Society, European Respiratory Society ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005, 171:912-930. American Thoracic Society, European Respiratory Society.
16. Palm JP, Graf P, Lundberg JON, Alving K. Characterization of exhaled nitric oxide: introducing a new reproducible method for nasal nitric oxide measurements. Eur Respir J 2000, 16:236-241. 10.1034/j.1399-3003.2000.16b09.x, 10968497.
17. Zetterquist W, Pedroletti C, Lundberg JON, Alving K. Salivary contribution to exhaled nitric oxide. Eur Resp J 1999, 13:327-333.
18. Shijubo N, Itoh Y, Yamaguchi T, Imada A, Hirasawa M, Yamada T, Kawai T, Abe S. Clara cell protein-positive epithelial cells are reduced in small airways of asthmatics. Am J Respir Crit Care Med 1999, 160:930-933.
19. de Burbure C, Pignatti P, Corradi M, Malerba M, Clippe A, Dumont X, Moscato G, Mutti A, Bernard A. Uteroglobin-related protein 1 and Clara cell protein in induced sputum of patients with asthma and rhinitis. Chest 2007, 131:172-179. 10.1378/chest.06-0835, 17218572.
20. Turner S. The role of exhaled nitric oxide in the diagnosis, management and treatment of asthma. Mini Rev Med Chem 2007, 7:539-542.
21. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, Pavord ID, Ratjen F, Silkoff PE, Taylor DR, Zamel N. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010, 138:682-692. 10.1378/chest.09-2090, 20822990.
22. Porsbjerg C, Lund TK, Pedersen L, Backer V. Inflammatory subtypes in asthma are related to airway hyperresponsiveness to mannitol and exhaled NO. J Asthma 2009, 46:606-612. 10.1080/02770900903015654, 19657904.
23. Maniscalco M, Sofia M, Pelaia G. Nitric oxide in upper airways inflammatory diseases. Inflamm Res 2007, 56:58-69. 10.1007/s00011-006-6111-1, 17431742.
24. Larsson AK, Bäck M, Hjoberg J, Dahlén SE. Inhibition of nitric-oxide synthase enhances antigen-induced contractions and increases release of cysteinyl-leucotrienes in guinea pig lung parenchyma: nitric oxide as a protective factor. J Pharmacol Exp Ther 2005, 315:458-465. 10.1124/jpet.105.086694, 16024733.
25. Larsson AK, Bäck M, Lundberg JO, Dahlén SE. Specific mediator inhibition by the NO donors SNP and NCX 2057 in the peripheral lung: implications for allergen-induced bronchoconstriction. Respir Res 2009, 10:46. 10.1186/1465-9921-10-46, 2696438, 19493362.
26. Coleman JW. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin Exp Immunol 2002, 129:4-10. 10.1046/j.1365-2249.2002.01918.x, 1906415, 12100016.
27. Lundberg JO. Airborne nitric oxide: inflammatory marker and aerocrine messenger in man. Acta Physiol Scand Suppl 1996, 633:1-27.
28. Maniscalco M, Sofia M, Carratù L, Higenbottam T. Effect of nitric oxide inhibition on nasal airway resistance after nasal allergen challenge in allergic rhinitis. Eur J Clin Invest 2001, 31:462-466. 10.1046/j.1365-2362.2001.00825.x, 11380599.
29. Moody A, Fergusson W, Wells A, Bartley J, Kolbe J. Nasal levels of nitric oxide as an outcome variable in allergic upper respiratory tract disease: Influence of atopy and hayfever on nNO. Am J Rhinol 2006, 20:425-429. 10.2500/ajr.2006.20.2921, 17063731.
30. Palm JP, Alving K, Lundberg JO. Characterization of airway nitric oxide in allergic rhinitis: the effect of intranasal administration of L-NAME. Allergy 2003, 58:885-892. 10.1034/j.1398-9995.2003.00098.x, 12911417.